VBI starts Phase III of Sci-B-Vac to prevent HBV infection

VBI Vaccines Inc. (NASDAQ:VBIV) began the double-blind, international Phase III PROTECT trial of Sci-B-Vac to prevent HBV infection in about 1,600 adults.

Subjects will receive a three-dose course of 10 μg Sci-B-Vac or Engerix-B from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). The co-primary endpoints are non-inferiority to Engerix-B in seroprotection rate four weeks after the third vaccination in patients ages ≥18 and superiority to Engerix-B four weeks after the third vaccination in patients ages ≥45. Secondary endpoints include speed of seroprotection and safety...